Allelotype Analysis of Resistant and Susceptible C.D2-Chr 4 Congenic Strains
Marker* . | Pos. (cM) . | MIA . | Pnd4 . | Pnd4A N15F6 . | Pnd4C N15F7 . | Fv1 N19F11 . | Pnd7 N12F9 . | Pnd7A N15F7 . | Pnd7B N14F8 . |
---|---|---|---|---|---|---|---|---|---|
. | . | N10F15 . | N12F14 . | . | . | . | . | . | . |
% PCT + at 300d | 0% | 6% | 38% | 18% | 14% | 21% | 20% | 42% | |
% PCT in BALB/c† | 43% | 37% | 42% | 42% | 37% | 57% | 43% | 42% | |
Pctr2 Phenotype | R = D | PR = D | S = C | PR = D | PR = D | PR = D | PR = D | S = C | |
Predicted Pctr1 | D | C | C | C | C | C | C | C | |
D4Mit84 | 37.7 | C | C | C | C | C | C | C | C |
Ifna, D4Mit27 | 42.6 | D | C | C | C | C | C | C | C |
D4Mit15 | 43 | D | C | C | C | C | C | C | C |
D4Mit153 | 45.5 | D | C | C | C | C | C | C | C |
D4Mit28 | 46 | D | C | C | C | C | C | C | C |
D4Mit119 | 49 | D | C | C | C | C | C | C | C |
D4Mit187 | 49 | D | C | C | C | C | C | C | C |
Mtv13, D4Mit31 | 49.5 | D | C | C | C | C | C | C | C |
Tal2 (Scl) | 49.5 | D | C | C | C | C | C | C | C |
D4Lgm1 | 50.6 | D | C | C | C | C | C | C | C |
D4Rck41 | 51 | D | D | D | C | C | C | C | C |
Ccnb1-rs10 | 50.7 | D | D | D | C | C | C | C | C |
D4Mit52 | 54.9 | D | D | D | C | C | C | C | C |
D4Mit57 | 56 | D | D | D | C | C | C | C | C |
D4Mit122 | 56 | D | D | D | C | C | C | C | C |
D4Mit37 | 56.5 | D | D | D | C | C | C | C | C |
D4Mit148 | 66 | D | D | C | C | D | C | C | C |
D4Mit284 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit312 | 69.8 | D | D | C | C | C | C | C | C |
Gt10 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit65 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit32 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit252 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit48 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit13 | 71 | D | D | C | C | C | C | C | C |
D4Mit126 | 71 | D | D | C | C | C | C | C | C |
D4Mit128 | 71 | D | D | C | C | C | C | C | C |
D4Mit343 | 71 | D | D | C | C | C | C | C | C |
D4Mit341 | 71 | D | D | C | D | C | C | C | C |
D4Lgm3 | 75.3 | D | D | C | D | C | C | C | C |
Tnfr2 (D4Mit233) | 75.5 | D | D | C | D | D | C | C | C |
D4Mit160 | 76 | D | D | C | D | D | C | C | C |
D4Mit340 | 76 | D | D | C | D | D | C | C | C |
D4Mit49 | 76 | D | D | C | D | D | C | C | C |
D4Mit259 | 76 | D | D | C | D | D | C | C | C |
D4Mit285 | 76 | D | D | C | D | D | C | C | C |
Xmv8 | 76.2 | D | D | C | D | D | C | C | C |
Xmv44 | 76.4 | D | D | C | D | D | D | D | D |
Xmv14 | 76.5 | D | D | C | D | D | D | D | D |
Xmv9 | 76.5 | D | D | C | D | D | D | D | D |
D4Rck128 | 76.5 | D | D | C | D | D | D | ||
Nppa (Pnd) | 76.5 | D | D | C | D | D | D | D | D |
Fv1 | 76.5 | D | D | C | D | D | D | D | D |
D4Nimr1 | 76.5 | D | D | C | D | D | D | D | D |
D4Mit310 | 77 | D | D | C | D | D | D | D | C |
D4Mit129 | 77 | D | D | C | D | D | D | D | C |
D4Mit190 | 79 | C | D | C | D | D | D | D | C |
D4Mit33 | 79 | C | D | C | D | D | D | D | C |
D4Mit226 | 79 | C | D | C | D | D | D | D | C |
D4Mit42 | 81 | C | D | C | D | D | D | D | C |
D4Mit180 | 81 | C | D | C | D | D | D | D | C |
D4Mit131 | 81.2 | C | D | C | D | D | D | D | C |
D4Mit253 | 81.2 | C | D | C | D | D | D | D | C |
D4Mit313 | 81.5 | C | D | C | D | D | D | C | C |
D4Mit254 | 81.7 | C | D | C | D | D | D | C | C |
Pkcz-rs | 81.9 | C | D | C | D | C | D | C | C |
D4Smh6b | 82 | C | D | C | D | C | D | C | C |
Marker* . | Pos. (cM) . | MIA . | Pnd4 . | Pnd4A N15F6 . | Pnd4C N15F7 . | Fv1 N19F11 . | Pnd7 N12F9 . | Pnd7A N15F7 . | Pnd7B N14F8 . |
---|---|---|---|---|---|---|---|---|---|
. | . | N10F15 . | N12F14 . | . | . | . | . | . | . |
% PCT + at 300d | 0% | 6% | 38% | 18% | 14% | 21% | 20% | 42% | |
% PCT in BALB/c† | 43% | 37% | 42% | 42% | 37% | 57% | 43% | 42% | |
Pctr2 Phenotype | R = D | PR = D | S = C | PR = D | PR = D | PR = D | PR = D | S = C | |
Predicted Pctr1 | D | C | C | C | C | C | C | C | |
D4Mit84 | 37.7 | C | C | C | C | C | C | C | C |
Ifna, D4Mit27 | 42.6 | D | C | C | C | C | C | C | C |
D4Mit15 | 43 | D | C | C | C | C | C | C | C |
D4Mit153 | 45.5 | D | C | C | C | C | C | C | C |
D4Mit28 | 46 | D | C | C | C | C | C | C | C |
D4Mit119 | 49 | D | C | C | C | C | C | C | C |
D4Mit187 | 49 | D | C | C | C | C | C | C | C |
Mtv13, D4Mit31 | 49.5 | D | C | C | C | C | C | C | C |
Tal2 (Scl) | 49.5 | D | C | C | C | C | C | C | C |
D4Lgm1 | 50.6 | D | C | C | C | C | C | C | C |
D4Rck41 | 51 | D | D | D | C | C | C | C | C |
Ccnb1-rs10 | 50.7 | D | D | D | C | C | C | C | C |
D4Mit52 | 54.9 | D | D | D | C | C | C | C | C |
D4Mit57 | 56 | D | D | D | C | C | C | C | C |
D4Mit122 | 56 | D | D | D | C | C | C | C | C |
D4Mit37 | 56.5 | D | D | D | C | C | C | C | C |
D4Mit148 | 66 | D | D | C | C | D | C | C | C |
D4Mit284 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit312 | 69.8 | D | D | C | C | C | C | C | C |
Gt10 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit65 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit32 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit252 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit48 | 69.8 | D | D | C | C | C | C | C | C |
D4Mit13 | 71 | D | D | C | C | C | C | C | C |
D4Mit126 | 71 | D | D | C | C | C | C | C | C |
D4Mit128 | 71 | D | D | C | C | C | C | C | C |
D4Mit343 | 71 | D | D | C | C | C | C | C | C |
D4Mit341 | 71 | D | D | C | D | C | C | C | C |
D4Lgm3 | 75.3 | D | D | C | D | C | C | C | C |
Tnfr2 (D4Mit233) | 75.5 | D | D | C | D | D | C | C | C |
D4Mit160 | 76 | D | D | C | D | D | C | C | C |
D4Mit340 | 76 | D | D | C | D | D | C | C | C |
D4Mit49 | 76 | D | D | C | D | D | C | C | C |
D4Mit259 | 76 | D | D | C | D | D | C | C | C |
D4Mit285 | 76 | D | D | C | D | D | C | C | C |
Xmv8 | 76.2 | D | D | C | D | D | C | C | C |
Xmv44 | 76.4 | D | D | C | D | D | D | D | D |
Xmv14 | 76.5 | D | D | C | D | D | D | D | D |
Xmv9 | 76.5 | D | D | C | D | D | D | D | D |
D4Rck128 | 76.5 | D | D | C | D | D | D | ||
Nppa (Pnd) | 76.5 | D | D | C | D | D | D | D | D |
Fv1 | 76.5 | D | D | C | D | D | D | D | D |
D4Nimr1 | 76.5 | D | D | C | D | D | D | D | D |
D4Mit310 | 77 | D | D | C | D | D | D | D | C |
D4Mit129 | 77 | D | D | C | D | D | D | D | C |
D4Mit190 | 79 | C | D | C | D | D | D | D | C |
D4Mit33 | 79 | C | D | C | D | D | D | D | C |
D4Mit226 | 79 | C | D | C | D | D | D | D | C |
D4Mit42 | 81 | C | D | C | D | D | D | D | C |
D4Mit180 | 81 | C | D | C | D | D | D | D | C |
D4Mit131 | 81.2 | C | D | C | D | D | D | D | C |
D4Mit253 | 81.2 | C | D | C | D | D | D | D | C |
D4Mit313 | 81.5 | C | D | C | D | D | D | C | C |
D4Mit254 | 81.7 | C | D | C | D | D | D | C | C |
Pkcz-rs | 81.9 | C | D | C | D | C | D | C | C |
D4Smh6b | 82 | C | D | C | D | C | D | C | C |
Shaded areas designate possible locations for the Pctr2 locus.
Abbreviations: Pos, consensus map position in cM from the centromere; N, backcross generations of the congenic; F, filial generations of the congenic; % PCT, percent of PCT-positive mice at day 300; R, resistant; D, DBA/2N; PR, partially resistant; S, susceptible; C, BALB/cAn.
Marker refers to the Chr 4 locus examined.
% PCT in BALB/c refers to the incidence of plasmacytomagenesis in 30 or 40 BALB/c controls tested simultaneously with the designated congenic strain.